B-type Natruiretic Peptide Levels Stratify the Risk for Arrhythmia Among Implantable Cardioverter Defibrillator Patients
Open Access
- 18 December 2008
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 31 (12) , 586-589
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarctionEP Europace, 2007
- Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapiesHeart, 2006
- Amino-Terminal Pro-Brain Natriuretic Peptide Predicts Ventricular Arrhythmogenesis in Patients With Ischemic Cardiomyopathy and Implantable Cardioverter-DefibrillatorsChest, 2005
- Heart Failure and the Risk of Shocks in Patients With Implantable Cardioverter DefibrillatorsCirculation, 2004
- Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking eraJACC, 2004
- Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and DeathNew England Journal of Medicine, 2004
- B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart FailureCirculation, 2002
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002
- Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT.Pacing and Clinical Electrophysiology, 2000
- A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular ArrhythmiasNew England Journal of Medicine, 1997